PURE Bioscience Faces Going Concern Doubt Amidst SDC Product Push

TL;DR

**PURE is a high-risk bet on innovative antimicrobial tech, but its going concern warning makes it a speculative play for traders.**

AI Summary

PURE Bioscience, Inc. (PURE) reported a market value of common stock held by non-affiliates at approximately $4,674,000 as of January 31, 2025, with 111,886,473 shares outstanding as of October 29, 2025. The company focuses on developing and commercializing proprietary antimicrobial products based on its patented Silver Dihydrogen Citrate (SDC) technology, targeting health and environmental challenges related to pathogen and hygienic control. Key products include PURE Hard Surface, an EPA-registered disinfectant and sanitizer, and PURE Control, an FDA-approved processing aid for poultry (FCN 1768) and produce (FCN 1600). PURE Hard Surface boasts kill times as fast as 30 seconds for pathogens like SARS-CoV-2 and E. coli, and is classified as EPA Category IV (lowest toxicity). PURE Control achieves up to a 6 log reduction in Salmonella on poultry. The company's strategy involves expanding its distribution network, partnering for international approvals, developing new SDC-based products, and protecting its intellectual property. Auditors have expressed substantial doubt about PURE's ability to continue as a going concern, highlighting limited capital and a history of losses.

Why It Matters

PURE Bioscience's continued operation is under auditor scrutiny due to substantial doubt about its going concern status, directly impacting investor confidence and the company's ability to fund future growth. For employees, this raises job security concerns, while customers relying on PURE Hard Surface and PURE Control for critical food safety applications could face supply chain disruptions if the company falters. In a competitive food safety market, PURE's SDC technology, with its superior efficacy and low toxicity, offers a distinct advantage, but its financial instability could prevent it from fully capitalizing on this innovation and challenging larger players. The broader market could lose a unique, environmentally responsible antimicrobial solution if PURE cannot secure additional capital.

Risk Assessment

Risk Level: high — The risk level is high due to the explicit statement that 'Our auditors have expressed substantial doubt about our ability to continue as a going concern.' This is further compounded by the company's 'limited capital' and 'history of losses,' indicating significant financial instability and an urgent need for additional funding to sustain operations.

Analyst Insight

Investors should approach PURE with extreme caution, recognizing the significant going concern risk. Await clear evidence of successful capital raises or a sustained path to profitability before considering any investment, as the current financial outlook is highly precarious.

Key Numbers

• $4,674,000 — Market value of common stock held by non-affiliates (as of January 31, 2025, indicating small market capitalization)
• 111,886,473 — Shares of common stock outstanding (as of October 29, 2025)
• 30 seconds — Fastest kill time for PURE Hard Surface (for pathogens like SARS-CoV-2 and E. coli)
• 6 log reduction — Efficacy of PURE Control (in Salmonella on treated poultry products)
• Category IV — EPA toxicity rating for PURE Hard Surface (lowest toxicity category, requiring no signal words)

Key Players & Entities

• PURE Bioscience, Inc. (company) — registrant
• ETIH20 Inc. (company) — wholly owned subsidiary
• U.S. Environmental Protection Agency (regulator) — approves SDC products
• U.S. Food and Drug Administration (regulator) — approves SDC products
• Health Canada (regulator) — approves SDC products
• Silver Dihydrogen Citrate (other) — patented core technology
• PURE Hard Surface (other) — EPA-registered disinfectant
• PURE Control (other) — FDA-approved food processing aid
• OTCBB (other) — market for common stock

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's auditors have expressed substantial doubt about PURE Bioscience, Inc.'s ability to continue as a going concern. This is primarily due to limited capital and a history of operating losses, which raise questions about its long-term financial viability.
• Limited Market Capitalization [medium — market]: As of January 31, 2025, the market value of common stock held by non-affiliates was approximately $4,674,000. This small market capitalization indicates a limited investor base and potential challenges in raising significant capital.
• Dependence on Distribution Network [medium — operational]: The company's strategy relies heavily on growing and supporting its distribution network to expand reach and achieve scalability. Any disruptions or inefficiencies in this network could significantly impact sales and market penetration.
• International Approval Delays [medium — regulatory]: PURE Bioscience aims to partner with third parties for international approvals of its SDC-based products. The process of obtaining these approvals can be lengthy and complex, potentially delaying international market entry and revenue generation.
• Product Development and Commercialization [medium — operational]: The company's success is contingent on its ability to develop additional proprietary products and applications leveraging its SDC technology. Failure to innovate or effectively commercialize new products could hinder growth.
• Intellectual Property Protection [low — legal]: Protecting and enhancing the company's intellectual property is a key strategic element. Challenges in defending patents or facing infringement claims could negatively impact its competitive advantage and financial performance.

Industry Context

PURE Bioscience operates in the antimicrobial and food safety solutions market, which is driven by increasing consumer demand for safe food and growing concerns about pathogen control. The market includes a range of disinfectant and sanitizer products, with a trend towards solutions offering high efficacy combined with low toxicity. Competition comes from established chemical manufacturers and newer entrants developing innovative technologies.

Regulatory Implications

The company's products are subject to rigorous regulatory oversight by agencies like the EPA (for disinfectants) and FDA (for food processing aids). Obtaining and maintaining these approvals is crucial for market access. The EPA's classification of PURE Hard Surface as Category IV (lowest toxicity) is a significant regulatory advantage.

What Investors Should Do

1. Monitor cash burn and future financing activities.
2. Evaluate the expansion of the distribution network.
3. Assess progress on international approvals and new product development.
4. Consider the implications of the low market capitalization.

Glossary

Silver Dihydrogen Citrate (SDC)

A patented technology platform developed by PURE Bioscience that forms the basis of its antimicrobial products. (This is the core proprietary technology that differentiates PURE's products and is central to its business strategy and product development.)

EPA-registered

A product that has been evaluated by the U.S. Environmental Protection Agency (EPA) and meets specific standards for safety and effectiveness for its intended use, such as disinfection. (Indicates that PURE Hard Surface has met regulatory requirements for sale and use as a disinfectant in the U.S., a key market.)

FDA-approved processing aid

A substance that is used during the processing of food but is not intended to be an ingredient in the finished food product, and has received approval from the U.S. Food and Drug Administration (FDA). (Highlights regulatory approval for PURE Control in food processing (poultry and produce), enabling its use in these critical food safety applications.)

Category IV (EPA toxicity rating)

The lowest toxicity category assigned by the EPA for pesticides and disinfectants, meaning the product has minimal risk to human health and the environment and requires no signal words on its label. (This classification for PURE Hard Surface is a significant selling point, indicating a favorable safety profile compared to many competing disinfectants.)

Log reduction

A measure of the effectiveness of a disinfectant or antimicrobial agent, indicating the factor by which the number of microorganisms has been reduced. A 6-log reduction means a 1,000,000-fold decrease in microbial count. (Quantifies the high efficacy of PURE Control in eliminating pathogens like Salmonella on poultry, a key performance metric for food safety.)

Going concern

A business assumption that a company will be able to continue operating for the foreseeable future, typically at least the next 12 months. If there is substantial doubt, it raises concerns about the company's ability to meet its obligations. (The auditors' substantial doubt about PURE's going concern status is a critical red flag for investors, indicating significant financial instability.)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and new risks, is not available in the provided text excerpt from the 10-K. The excerpt focuses on the current business strategy, products, and risk factors, including a significant going concern warning from auditors.

Key Financial Figures

• $0.01 — ction 12(g) of the Act: Common Stock, $0.01 par value Indicate by check mark whet

Filing Documents

• form10-k.htm (10-K) — 1277KB
• ex4-3.htm (EX-4.3) — 30KB
• ex23-1.htm (EX-23.1) — 4KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 9KB
• ex32-2.htm (EX-32.2) — 10KB
• form10-k_001.jpg (GRAPHIC) — 25KB
• form10-k_002.jpg (GRAPHIC) — 24KB
• 0001493152-25-020065.txt ( ) — 5564KB
• pure-20250731.xsd (EX-101.SCH) — 32KB
• pure-20250731_cal.xml (EX-101.CAL) — 47KB
• pure-20250731_def.xml (EX-101.DEF) — 179KB
• pure-20250731_lab.xml (EX-101.LAB) — 358KB
• pure-20250731_pre.xml (EX-101.PRE) — 297KB
• form10-k_htm.xml (XML) — 607KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 11 Item 1B. Unresolved Staff Comments 26 Item1C. Cybersecurity 26 Item 2.

Properties

Properties 26 Item 3.

Legal Proceedings

Legal Proceedings 26 Item 4. Mine Safety Disclosures 26 Part II Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 27 Item 6. [Reserved] 28 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 34 Item 8. Consolidated Financial Statements and Supplementary Data 34 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 34 Item 9A.

Controls and Procedures

Controls and Procedures 34 Item 9B. Other Information 34 Item 9C. Disclosure Regarding Foreign Jurisdiction that Prevent Inspections 34 Part III Item 10. Directors, Executive Officers and Corporate Governance 35 Item 11.

Executive Compensation

Executive Compensation 40 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 45 Item 13. Certain Relationships and Related Transactions, and Director Independence 47 Item 14. Principal Accountant Fees and Services 48 Part IV Item 15. Exhibits and Financial Statement Schedules 49

Signatures

Signatures 51 2 CAUTIONARY Certain of Section 27A of the Securities Act of 1933, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by words such as "if," "shall," "may," "might," "will likely result," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "goal," "objective," "predict," "potential" or "continue," or the negative of these terms and other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. Additionally, statements concerning future matters such as our business strategy, development of new products, regulatory approvals, sales levels, expense levels, cash flows, future commercial and financing matters, future partnering opportunities and other statements regarding matters that are not historical are forward-looking statements. Although the forward-looking statements in this Annual Report reflect our good faith judgment, based on currently available information, they involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in the "Risk Factors" contained in Part I, Item 1A of this Annual Report. As a result of these factors, we cannot assure you

Business

Business Strategy Our goal is to establish a sustainable company by commercializing SDC-based products developed through our proprietary technology platform. We aim to deliver leading antimicrobial solutions that tackle food safety risks across the entire food industry supply chain. Our products are sold directly to end-use customers and through our expanding distribution network. Key elements of our business strategy include: 1. Growing and supporting our distribution network. Expanding sales through distribution provides the following: a. Expanded Reach: Distributors often have established networks and customer relationships, allowing us to access new markets and customer segments more efficiently. b. Cost Savings: Utilizing distributors can reduce overhead costs associated with logistics, warehousing, and inventory management. c. Market Knowledge: Distributors typically have local market insights and expertise, helping us navigate regional preferences and regulatory requirements. d. Faster Time to Market: Distributors can accelerate product availability in geographic regions throughout the country, enabling quicker responses and shortening the sales cycle. e. Sales Support: Distributors provide additional sales resources and support, such as training and promotional activities, enhancing product visibility. f. Scalability: Distributors can easily scale operations to accommodate growth without requiring significant investment from the manufacturer. g. Customer Service: Local distributors can offer better customer support, including faster response times and tailored services to meet specific client needs. 2. Continuing to partner with third parties seeking, or intending to seek, approvals to market SDC-based products outside the U.S. 3. Developing additional proprietary products and applications. 4. Protecting and enhancing our intellectual property. In addition to our existing food safety products, we plan to leverage our tech

View Full Filing

View this 10-K filing on SEC EDGAR